Preliminary data from the INSIGHT 2 study suggest that the combination of tepotinib and osimertinib has activity in patients with EGFR -mutated advanced non-small-cell lung cancer with MET amplification who have progressed on first-line osimertinib.

The committee highlights the benefits of tepotinib in this patient population, namely the objective response rate and response duration, as demonstrated in the phase 2 VISION trial .

medwireNews : The MET inhibitor tepotinib has received accelerated approval from the US FDA  for the treatment of metastatic non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations.

Individuals with advanced non-small-cell lung cancer positive for MET exon 14 skipping mutations could benefit from treatment with the selective MET inhibitor tepotinib, suggests a phase 2 trial.

Furthermore, this group comprised nine treatment-naïve individuals, 18 who had received a median 1.5 lines of prior treatment not including a MET–TKI, and 28 who had received a median 3.0 lines of treatment that included the MET–TKIs tepotinib or capmatinib.

Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

Although crizotinib was the first MET tyrosine kinase inhibitor to be evaluated in this patient group, promising data have since been reported for the more selective agents capmatinib, tepotinib, and savolitinib, say the researchers.

Combining the highly selective MET inhibitor tepotinib with gefitinib could benefit patients with non-small-cell lung cancer that has progressed on first-line treatment with an EGFR–tyrosine kinase inhibitor and has high levels of MET, suggest phase II trial results.